Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab

Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add ... Read More